Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
CDK4/6 inhibitors for metastatic breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.10.16
Views: 2197

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Dr Curigliano speaks with ecancertv at ESMO 2016 about CDK4/6 inhibitors, which he describes as changing the landscape in metastatic breast cancer.

Quoting results from MONALEESA2, as presented by Dr Gabriel Hortobayi, he weighs up data on adverse events, which had increased slightly from the preceeding PALOMA-2 trial.

With abemaciclib in mind, Dr Curigliano expects a place for CDK4/6 inhibitors in neo-adjuvant therapy, especially for patients with susceptible genotypes.

Abemaciclib was discussed further by Dr Sara Hurvitz with ecancerlearning, with video coming soon.

ecancer hosted a special symposium at ESMO 2016 focussing on CDK 4/6 inhibition which can be viewed here.

Supported by a grant from Pfizer Inc.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation